IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by Mogy Joel R Investment Counsel Inc.

Mogy Joel R Investment Counsel Inc. increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.0% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 70,460 shares of the company’s stock after acquiring an additional 699 shares during the period. IDEXX Laboratories makes up approximately 3.0% of Mogy Joel R Investment Counsel Inc.’s holdings, making the stock its 13th largest holding. Mogy Joel R Investment Counsel Inc.’s holdings in IDEXX Laboratories were worth $39,109,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IDXX. Patron Partners LLC increased its holdings in shares of IDEXX Laboratories by 2.7% in the 4th quarter. Patron Partners LLC now owns 765 shares of the company’s stock valued at $425,000 after acquiring an additional 20 shares during the last quarter. NewEdge Wealth LLC increased its holdings in shares of IDEXX Laboratories by 3.1% in the 4th quarter. NewEdge Wealth LLC now owns 659 shares of the company’s stock valued at $366,000 after acquiring an additional 20 shares during the last quarter. Phoenix Holdings Ltd. increased its holdings in shares of IDEXX Laboratories by 2.8% in the 3rd quarter. Phoenix Holdings Ltd. now owns 769 shares of the company’s stock valued at $338,000 after acquiring an additional 21 shares during the last quarter. BluePath Capital Management LLC increased its holdings in shares of IDEXX Laboratories by 1.8% in the 4th quarter. BluePath Capital Management LLC now owns 1,197 shares of the company’s stock valued at $663,000 after acquiring an additional 21 shares during the last quarter. Finally, Valley National Advisers Inc. increased its holdings in shares of IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after acquiring an additional 22 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently commented on IDXX. Barclays upped their price objective on IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. The Goldman Sachs Group upped their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Piper Sandler downgraded IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective for the company. in a research note on Tuesday, January 30th. JPMorgan Chase & Co. upped their price objective on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Finally, William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $591.50.

Insider Activity

In other news, SVP George Fennell sold 8,198 shares of the business’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the sale, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the transaction, the chief executive officer now directly owns 79,247 shares of the company’s stock, valued at $45,377,624.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP George Fennell sold 8,198 shares of the company’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares in the company, valued at $3,851,815.44. The disclosure for this sale can be found here. Insiders sold a total of 43,524 shares of company stock worth $24,871,960 over the last 90 days. 2.11% of the stock is currently owned by company insiders.

IDEXX Laboratories Stock Performance

IDXX stock traded up $10.06 during trading on Friday, reaching $499.30. 529,834 shares of the company’s stock were exchanged, compared to its average volume of 416,262. The company has a quick ratio of 1.17, a current ratio of 1.57 and a debt-to-equity ratio of 0.42. IDEXX Laboratories, Inc. has a 1-year low of $372.50 and a 1-year high of $583.39. The company’s fifty day moving average price is $531.02 and its 200-day moving average price is $510.75. The firm has a market cap of $41.47 billion, a PE ratio of 49.58, a P/E/G ratio of 3.77 and a beta of 1.26.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, beating the consensus estimate of $2.12 by $0.20. The business had revenue of $901.60 million during the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The company’s revenue was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.05 earnings per share. On average, research analysts expect that IDEXX Laboratories, Inc. will post 11.15 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.